This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Fred Khosravi and AccessClosure (C)
Hamermesh, Richard G.; Barley, LaurenCase HBS-814074-EEntrepreneurshipOn September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It wa...Starting at €5.74
-
Whose Money Is It Anyway (C)
Narayanan, V.G.; Hamermesh, Richard G.; Gordon, RachelCase HBS-810031-EAccounting and ControlThe case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.Starting at €5.74
-
Whose Money Is It Anyway (A), (B), and (C), Teaching Note
Hamermesh, Richard G.; Narayanan, V.G.; Gordon, RachelTeaching Note HBS-111128-EAccounting and ControlTeaching Note for 810-008, 810-013, and 810-031.Starting at €0.00
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20